How We Mark Time and How Time Marks Us
Dr. Gotlib discusses the road to approval of midostaurin for the treatment of advanced systemic mastocytosis.
Abrogating Early Treatment Resistance in Early T-cell Precursor Acute Lymphoblastic Leukemia
Dr. Raetz looks at a study that shows response-based therapy in both children and adults with ETP-ALL is effective.
Dr. DeBaun reviews studies that debunk the misconception that sickle cell trait is associated with common medical morbidities.
Part 1 of this podcast features Drs. Cuker and Schünemann, and Part 2 includes Drs. Cushman and Monagle discussing the ASH Guidelines on VTE, specifically two now open for public comment.
Dr. Linkins reviews the WOMAN study, which proves the usefulness of tranexamic acid to reduce maternal mortality due to postpartum hemorrhage.
July/August 2017 Volume 14, Issue 4
View all Features articles
View all Diffusion articles
Dr. Kenneth Anderson outlines six major ASH strategic initiatives and goals for the coming years discussed at the 2017 Execxutive Committee Spring Retreat in Canada.
View all president's column articles
View all Ask the Hematologist articles
View all Op-Ed articles
View all Mini Review articles
On July 13, 2017, the U.S. Senate released an updated
version of the Better Care Reconciliation Act (BCRA), legislation to repeal
large provisions of the Affordable Care Act (ACA).
Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations.
On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model. CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.
ASH is pleased to see the National Heart, Lung and Blood Institute’s (NHLBI) continuous support (RFA-HL-15-030) for the development of improved techniques to enhance the production of clinically relevant, functional stem cell-derived red blood cells or platelets.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology